Brighton Jones LLC Trims Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Brighton Jones LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the second quarter, HoldingsChannel.com reports. The fund owned 11,806 shares of the biopharmaceutical company’s stock after selling 271 shares during the period. Brighton Jones LLC’s holdings in Gilead Sciences were worth $810,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. lifted its position in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the period. Palisade Asset Management LLC bought a new position in Gilead Sciences in the first quarter worth about $29,000. Frank Rimerman Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter worth about $36,000. Fortis Group Advisors LLC boosted its position in Gilead Sciences by 100.0% during the 4th quarter. Fortis Group Advisors LLC now owns 492 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 246 shares in the last quarter. Finally, Pingora Partners LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $41,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GILD shares. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler restated an “overweight” rating and set a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a research note on Monday, September 16th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday, July 8th. Finally, Truist Financial raised their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $82.06.

Gilead Sciences Trading Up 0.0 %

Shares of NASDAQ:GILD opened at $83.94 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The stock’s fifty day moving average price is $76.95 and its 200-day moving average price is $71.26. The company has a market cap of $104.58 billion, a P/E ratio of 233.17, a PEG ratio of 2.80 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Sell-side analysts expect that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.67%. Gilead Sciences’s payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,002,940 in the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.